ClinicalTrials.gg
RecruitingNCT07339904ProLARSUpdated Jan 14, 2026

ProLARS Trial: Prospective Longitudinal Follow-up of Low Anterior Resection Syndrome (LARS) and COREFO Score After Rectum Surgery in Patients Undergoing Upfront Surgery or Different Neo-adjuvant Treatment Regimens

An interventional study of Questionnaire in Rectal Adenocarcinoma, LARS - Low Anterior Resection Syndrome and Rectal Resection, sponsored by University Hospital, Antwerp. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by University Hospital, Antwerp · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2024, registered Apr 2025).
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Rectal Neoplasms with a site in Belgium — 10 open to participants now, 20 under way, 4 of them phase 3. Rectal Neoplasms · Belgium.

Planned enrollment
28th of 45
100 · median 156
Started
2024
with 5 others
No phase
13 of 56
5 open now
Primary completion
2029-08
later than 14 of 19 live
Registered
54th of 56
by date

Among the 56 studies in Rectal Neoplasms with a site in Belgium, this one is the 28th largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2024, is one of 13 with no phase, reaches primary completion later than 14 of the 19 other live ones, and was the 54th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

10 of the 56 studies in Rectal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Rectal Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

OBJECTIVE Low anterior resection syndrome (LARS) is a term for functional bowel complaints occurring after low anterior resection. Symptoms can range from faecal incontinence and frequent loose stools to urgency and incomplete emptying with great impact on quality of life. Little is known about the longitudinal evolution of LARS and the impact of different schedules of neoadjuvant chemoradiotherapy combined with surgery.

The investigators aim to investigate the incidence and evolution of functional bowel complaints in function of different neoadjuvant treatment regimens, type of surgery and adjuvant therapy in patients who undergo surgery for rectal cancer. The investigators focus on following objectives: evolution of LARS- and COREFO-scores per treatment regimen and their impact on work incapacity; identification of possible risk factors potentially related to functional outcome; monitoring and treatment of LARS.

METHODS This will be a multicentre prospective interventional study. The study population will consist of adult patients with rectal cancer, regardless of any neo-adjuvant therapy. Patients will be included for 5 years with a 2 year postoperative follow-up. Interim analysis will be made after 2 years of inclusion. Patients with intellectual disability or clinical colon obstruction are excluded. Automated online questionnaires including LARS and COREFO scores, incapacity for work and defecation quality will be sent at different time points (figure 1) using REDCap.

RESULTS and CONCLUSIONS Longitudinal change of LARS- and COREFO-scores will be visually summarized. Patient, disease or procedure specific risk factors will be assessed as well.

LARS is proven to be the principal postoperative problem after rectal surgery. If the investigators can predict the severity of LARS (minor or major LARS), this can be extremely helpful in deciding whether to perform a sphincter-sparing resection or a rectal amputation instead. Furthermore, the investigators want to offer perspective to patients who are susceptible to a disturbed postoperative bowel function.

03

Conditions studied

  • Rectal Adenocarcinoma
  • LARS - Low Anterior Resection Syndrome
  • Rectal Resection
  • Low Anterior Resection
  • Total Mesorectal Excision

Keywords

  • LARS
  • Rectal resection
  • Total mesorectal excision
  • Low anterior resection
  • Rectal carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older.
  • Diagnosis of rectal cancer, discussed at the multidisciplinary consultation, with the intention to perform a sphincter preserving total mesorectal excision (TME) or partial mesorectal excision (PME), regardless of the need of treatment.

Exclusion criteria

Exclusion Criteria:

  • History of inflammatory bowel disease (Crohn's disease, ulcerative colitis) due to often persistent bowel complaints and therefore distorted baseline and follow-up data.
  • Dementia or intellectual disability.
  • Patients who are obstructive and in need a decompressive stoma or rectal stenting due to the lack of baseline data as they are often admitted to the hospital in an urgent setting
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Upfront surgery

    Patients who undergo rectal resection without neo-adjuvant therapy

    Other: Questionnaire

  • Other
    Neo-adjuvant therapy

    Patients who receive neo-adjuvant therapy before undergoing rectal surgery

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    Online questionnaire regarding LARS- and COREFO-scores, quality of defecation process, incapacity for work and initiation of treatment for potential LARS at different moments in time

06

What researchers measure

Primary outcomes

  1. The evolution of the COREFO-score (Colorectal Functional Outcome questionnaire) at 2 years after rectal surgery compared to baseline (absolute difference) will be examined

    27 questions on 5-point Likert scale Higher score = worse bowel function

    Time frame: 2 years from when rectal resection or stoma reversal was performed

Secondary outcomes

  1. Evolution of LARS-score (low anterior resection syndrome) at 2 years after rectal surgery compared to baseline (absolute difference)

    0-20 = no LARS 21-29 = minor LARS 30-42 = major LARS

    Time frame: 2 years from when rectal resection or stoma reversal was performed

  2. The evolution of the LARS-score (low anterior resection syndrome) at 2 years after rectal surgery compared to baseline (relative difference) will be examined.

    0-20 = no LARS 21-29 = minor LARS 30-42 = major LARS

    Time frame: 2 years from when rectal resection or stoma reversal was performed

  3. The evolution of the COREFO-score (Colorectal Functional Outcome questionnaire) at 2 years after rectal surgery compared to baseline (relative difference) will be examined

    27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100)

    Time frame: 2 years from when rectal resection or stoma reversal was performed

  4. The evolution of the LARS-score (low anterior resection syndrome) in the absence of baseline data will be examined as well (absolute difference), comparing 2-year outcome to earliest results.

    0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42)

    Time frame: 2 years from when rectal resection or stoma reversal was performed

  5. The evolution of the LARS-score (low anterior resection syndrome) in the absence of baseline data will be examined as well (relative difference), comparing 2-year outcome to earliest results.

    0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42)

    Time frame: 2 years from when rectal resection or stoma reversal was performed

  6. The evolution of the COREFO-score (Colorectal Functional Outcome questionnaire) in the absence of baseline data will be examined as well (absolute difference), comparing 2-year outcome to earliest results.

    27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100)

    Time frame: 2 years from when rectal resection or stoma reversal was performed

  7. The evolution of the COREFO-score (Colorectal Functional Outcome questionnaire) in the absence of baseline data will be examined as well (relative difference), comparing 2-year outcome to earliest results.

    27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100)

    Time frame: 2 years from when rectal resection or stoma reversal was performed

  8. LARS-score (low anterior resection syndrome) score at diagnosis

    0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42) LARS = low anterior resection syndrome Using a questionnaire Unit = mean score (0-42)

    Time frame: At diagnosis = baseline

  9. COREFO-score at diagnosis (Colorectal Functional Outcome questionnaire)

    27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100) COREFO = Colorectal Functional Outcome questionnaire Using a questionnaire Unit = mean score (0-100)

    Time frame: At diagnosis = baseline

  10. LARS-score (low anterior resection syndrome) after neo-adjuvant therapy

    0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42) LARS = low anterior resection syndrome Using a questionnaire Unit = mean score (0-42)

    Time frame: After neo-adjuvant therapy (up to 6 months from baseline)

  11. COREFO-score after neo-adjuvant therapy (Colorectal Functional Outcome questionnaire)

    27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100) COREFO = Colorectal Functional Outcome questionnaire Using a questionnaire Unit = mean score (0-100)

    Time frame: After neo-adjuvant therapy (up to 6 months from baseline)

  12. LARS-score (low anterior resection syndrome) shortly prior to surgery when there is a delay of 4 or more weeks after finishing neoadjuvant therapy

    0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42) LARS = low anterior resection syndrome Using a questionnaire Unit = mean score (0-42)

    Time frame: 2 days prior to surgery

  13. COREFO-score (Colorectal Functional Outcome questionnaire) shortly prior to surgery when there is a delay of 4 or more weeks after finishing neoadjuvant therapy

    27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100) COREFO = Colorectal Functional Outcome questionnaire Using a questionnaire Unit = mean score (0-100)

    Time frame: 2 days prior to surgery

  14. LARS-scores (low anterior resection syndrome) postoperatively after 1 month, 3 months, 6 months, 1 year and 2 years

    0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42) LARS = low anterior resection syndrome Using a questionnaire Unit = mean score (0-42)

    Time frame: Postoperatively after 1 month, 3 months, 6 months, 1 year and 2 years

  15. COREFO-scores (Colorectal Functional Outcome questionnaire) postoperatively after 1 month, 3 months, 6 months, 1 year and 2 years

    27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100) COREFO = Colorectal Functional Outcome questionnaire Using a questionnaire Unit = mean score (0-100)

    Time frame: Postoperatively after 1 month, 3 months, 6 months, 1 year and 2 years

  16. Evolution of quality of defecation process

    Visual analogue scale 0-10 0 = worst defecation ever 10 = best defecation ever

    Time frame: 2 years after rectal resection or stoma reversal

  17. Incapacity for work

    Time (days) between date of start work incapacity and date back to work (if not yet retired)

    Time frame: At diagnose (baseline), 2 days after radiotherapy, 1 week after chemotherapy and 1 month after rectal resection

  18. Initiation of treatment for potential LARS (low anterior resection syndrome) during follow-up

    Yes/no: * Dietary measures * Medication (probiotics, antidiarrheals, ...) * Pelvic floor physiotherapy * Transanal irrigation, rectal irrigation, enema * Neuromodulation (neurostimulator) * Other Calculating proportion of patients who received treatment for LARS

    Time frame: Up to 2 years after rectal resection

Other outcomes

  1. Gender

    Male, female, other

    Time frame: Baseline

  2. Year of birth

    Year of birth

    Time frame: Baseline

  3. Age

    Age at diagnosis and at surgery

    Time frame: Baseline to date of surgery

  4. Hospital admission data

    Length of stay in days (date of admission for rectal resection until date of dismission)

    Time frame: After rectal resection

  5. Medical history

    Smoking, diabetes mellitus, abdominal, cardiac, pulmonary (yes/no)

    Time frame: Baseline

  6. Anthropometry

    Body mass index (kg/m²)

    Time frame: Baseline

  7. Tumor location

    Distance in cm from recto-anal angle, based on MRI

    Time frame: After restaging prior to surgery

  8. Presence of lateral lymph nodes

    Presence of lateral lymph nodes (yes/no)

    Time frame: After restaging prior to surgery

  9. cTNM

    Clinical TNM classification of tumor: * T: tumor size * N: nodal involvement * M: metastasis

    Time frame: After restaging prior to surgery

  10. Percentage of rectal circumference involved

    Percentage of rectal circumference involved: on imaging (CT/MRI), coloscopy or ultrasound-endoscopy

    Time frame: After restaging prior to surgery

  11. Circumferential resection margin

    Circumferential resection margin (CRM; on MRI; measured from gland; in mm)

    Time frame: After restaging prior to surgery

  12. Neoadjuvant therapy

    The eventual use of neoadjuvant therapy: radiotherapy (RT), chemotherapy (CT) (yes/no)

    Time frame: From baseline to surgery

  13. Radiotherapy dose

    Radiotherapy dose (Gy)

    Time frame: From baseline to surgery

  14. Chemotherapy type and frequency

    Certain type of chemotherapy, used for certain amount of cycles

    Time frame: From baseline to surgery

  15. Surgical approach

    Surgical approach: * Open * Laparoscopy * Robot * Transanal (TaTME)

    Time frame: At surgery

  16. Configuration of anastomosis

    Configuration of colorectal/coloanal anastomosis: * End-to-End * Side-to-End * End-to-Side * Side-to-Side

    Time frame: At surgery

  17. Manual or stapled anastomosis

    Manual or stapled anastomosis

    Time frame: At surgery

  18. Conversion

    Conversion during surgery: * Robot to laparoscopy (yes/no) * Laparoscopy to open (yes/no)

    Time frame: At surgery

  19. Diverting ileostomy

    Use of a diverting ileostomy (yes/no)

    Time frame: At surgery

  20. Baseline CEA

    Baseline CEA: Carcinoembryonic antigen (µg/L)

    Time frame: At baseline

  21. Histology type

    Histology type of tumor (adenocarcinoma, squamous cell carcinoma, neuro-endocrine tumor etc.)

    Time frame: After surgery

  22. Tumor differentiation

    Well differentiated Moderately differentiated poorly differentiated

    Time frame: After surgery

  23. Tumor perforation

    Tumor perforation on histology (yes/no)

    Time frame: After surgery

  24. Radical resection

    Radical resection: R0, R1, R2

    Time frame: After surgery

  25. pTNM

    Pathological TNM classification of tumor * T: tumor size * N: nodal involvement * M: metastasis

    Time frame: After surgery

  26. Disease free interval

    Disease free interval: the period of time between the primary treatment of a malignancy and the first sign of tumor recurrence (in months)

    Time frame: Up to 2 years after rectal resection

  27. Type of complication

    Type of complication: * Urinary tract infection * Pulmonary complications * Surgical site infection * Intra-abdominal collections/abscess * Eventration/evisceration * Ileus * Small bowel obstruction * Anastomotic leakage * Deep venous thrombosis * Postoperative bleeding * Acute renal failure * High output ileostomy * Other stoma related complications * Other (yes/no)

    Time frame: After rectal resection during admission

  28. Early complications

    Early complications: before 30 days after surgery

    Time frame: Between surgery and 30 days after surgery

  29. Late complications

    Late complications: more than 30 days after surgery

    Time frame: From 30 days after surgery up to 2 years after surgery

  30. Anastomotic leakage

    Definition of anastomotic leakage: * Clinically manifest insufficiency of the anastomosis leading to a clinical state requiring treatment, diagnosed in accordance with surgical practice guidelines by a senior surgeon (no additional or systematic routine iconography nor colonoscopy) * Radiological evidence of anastomotic leakage if the patient is clinically symptomatic. Fistulas communicating with the anastomosis on CT scan are classified as AL together with presacral abscesses if extravasation of the colonic contrast is visible on radiological imaging (ref. SAFE 2019 Clinical Investigation Plan) (yes/no)

    Time frame: Up to 3 months after surgery

  31. Clavien-Dindo classification

    Clavien-Dindo classification (grade 0, I, II, IIIa, IIIb, IVa, IVb, V): Grade I: Minor deviation from normal course; no drugs or interventions needed (only supportive care). Grade II: Requires pharmacological treatment (e.g. antibiotics, blood transfusion, TPN). Grade III: Requires surgical, endoscopic, or radiological intervention IIIa: without general anesthesia IIIb: with general anesthesia Grade IV: Life-threatening complication requiring ICU care IVa: single-organ dysfunction IVb: multi-organ dysfunction Grade V: Death

    Time frame: After admission for rectal resection

  32. CCI-score

    CCI-score: comprehensive complication index (score from 0-100 calculated with online calculator: https://www.cci-calculator.com/cci-calculator)

    Time frame: After admission for rectal resection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2029, 60 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 60 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2025
First posted
Jan 14, 2026
StartActual
Aug 26, 2024
Primary completionEst.
Aug 2029
CompletionEst.
Aug 2029
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07339904
Responsible party
Niels Komen (MD, PhD, Head of the Abdominal Surgery Department, Principal Investigator, Clinical Professor, University Hospital, Antwerp) — Principal investigator
First posted
Jan 14, 2026
Start date
Aug 26, 2024
Primary completion
Aug 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Jan 14, 2026

Study contacts

Niels Komen, MD PhD
Contact
niels.komen@uza.be
+32 3 821 30 00
Juul Meurs, MD
Contact
juul.meurs@gmail.com
+32476617623
Niels Komen, MD PhD
principal investigator · University Hospital, Antwerp

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion